PLAU and neoplasm: Our previous experience using celecoxib to inhibit eicosanoid production, the fact that celecoxib affects uPA production and the conflicting findings regarding the role of uPA and PAI-1 in tumor progression caused us to investigate the expression of uPA and PAI-1 in the breast and uPA systemically before and after treatment with low (200 mg bid) and high (400 mg bid) dose celecoxib.